← Back to Search

Stem Cell Therapy

CardiAMP Cell Therapy for Heart Failure

N/A
Recruiting
Led By Amish Raval, MD
Research Sponsored by BioCardia, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
New York Heart Association (NYHA) Class II or III
Diagnosis of chronic ischemic left ventricular dysfunction secondary to myocardial infarction (MI) as described in the study protocol.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through study completion, maximum of two years
Awards & highlights

Summary

"This trial aims to test the safety and effectiveness of a new treatment called CardiAMP cell therapy system in patients with heart failure caused by reduced blood flow to the heart. The study will involve multiple medical

Who is the study for?
This trial is for people with heart failure due to past heart attacks, who have a weak pumping function (ejection fraction between 20-40%), and certain blood test results. They must be on stable heart medications for at least three months. It's not open to those outside these criteria.
What is being tested?
The study tests if injecting one's own processed bone marrow cells into the heart can improve its function in patients with ischemic heart failure. Participants are randomly assigned to receive either this cell therapy or just a diagnostic procedure.
What are the potential side effects?
Potential side effects may include discomfort at the bone marrow extraction site, infection risk from injections, allergic reactions, and irregular heartbeat. However, specific side effects will depend on individual patient responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My heart condition moderately affects my daily activities.
Select...
My heart's left side is weak due to a past heart attack.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through study completion, maximum of two years
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through study completion, maximum of two years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Primary Efficacy Endpoint
Secondary study objectives
Fifth Secondary Endpoint
First Secondary Endpoint
Fourth Secondary Endpoint
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Study (ABM MNC) TreatmentExperimental Treatment1 Intervention
Left ventricular catheterization with treatment consisting of autologous bone marrow mononuclear cells (ABM MNC) processed and delivered using the CardiAMP cell therapy system
Group II: Control TreatmentPlacebo Group1 Intervention
Left ventricular (diagnostic) catheterization but no administration of ABM MNC

Find a Location

Who is running the clinical trial?

BioCardia, Inc.Lead Sponsor
5 Previous Clinical Trials
506 Total Patients Enrolled
2 Trials studying Heart Failure
134 Patients Enrolled for Heart Failure
Amish Raval, MDPrincipal InvestigatorUniversity of Wisconsin, Madison
2 Previous Clinical Trials
468 Total Patients Enrolled
1 Trials studying Heart Failure
125 Patients Enrolled for Heart Failure
~167 spots leftby Apr 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top